Ustekinumab use in patients with severe psoriasis co-infected with hepatitis B and/or C

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

(2017) Igor Snast et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C

(2016) Monica Salvi   World Journal of Clinical Cases

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

(2013) H.-Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis treated with ustekinumab in a patient with hepatitis C

(2013) Adriana Abuchar et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

(2012) R. Navarro et al.   BRITISH JOURNAL OF DERMATOLOGY

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

(2011) Mauro Viganò et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

(2007) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY